Sufentanil Powder is an opioid antagonist. Sufentanil has the action of a Full Opioid Agonist. Powder SufentanilSufentanil is a type of opioid analgesic that can be used as an anesthetic adjunct, a balanced anesthetic agent, or a primary anesthetic agent. Sufentanil Powder can be given intravenously, epidurally, or orally. The sublingual form, also known as Dsuvia, is used to treat acute pain in adults that are severe enough to warrant the use of an opioid analgesic in certified medically supervised healthcare settings such as hospitals, surgical centers, and emergency departments. If analgesia is required immediately, the US military may consider using the sublingual form in the future.
Drug and Medication Information
Drug Indication of Sufentanil Powder
The indications for this drug are as follows:
- 1. As an analgesic adjunct in the maintenance of balanced general anesthesia in patients who are intubated and ventilated.
- 2. As a primary anesthetic agent for the induction and maintenance of anesthesia with 100% oxygen in patients undergoing major surgical procedures, in patients who are intubated and ventilated, such as cardiovascular surgery or neurosurgical procedures in the sitting position, to provide favorable myocardial and cerebral oxygen balance or when extended postoperative ventilation is anticipated.
- 3. For epidural administration as an analgesic combined with a low dose (usually 12.5 mg per administration) bupivacaine usually during labor and vaginal delivery.
- 4. The sublingual form is indicated for the management of acute pain in adults that is severe to warrant the use of an opioid analgesic in certified medically supervised healthcare settings, including hospitals, surgical centers, and emergency departments.
Mechanism of Action
Sufentanil Powder is a synthetic, potent opioid that binds to?-opioid receptors with high selectivity [F2009]. These receptors are found in abundance in the human brain, spinal cord, and other tissues [A39636], [A39637]. Opioids, in general, reduce cAMP (affecting neural signaling pathways), decrease neurotransmitter release, and cause membrane hyperpolarization, all of which contribute to pain relief [A39637]. Opiate receptors are linked to G-protein receptors and act as both positive and negative regulators of synaptic neural transmission by activating effector proteins via G-proteins. When the opiate receptor binds, the G-protein complex exchanges GTP for GDP. Because adenylate cyclase and cAMP are located at the inner surface of the plasma membrane, opioids reduce intracellular cAMP by inhibiting adenylate cyclase.